Trade Innoviva - INVA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | - | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | N/A |
Open* | N/A |
1-Year Change* | N/A |
Day's Range* | N/A |
52 wk Range | 10.64-20.71 |
Average Volume (10 days) | 972.32K |
Average Volume (3 months) | 14.60M |
Market Cap | 773.23M |
P/E Ratio | 4.86 |
Shares Outstanding | 68.13M |
Revenue | 331.34M |
EPS | 2.33 |
Dividend (Yield %) | N/A |
Beta | 0.58 |
Next Earnings Date | Apr 25, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|
Innoviva Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 331.339 | 391.866 | 336.794 | 261.016 | 261.004 |
Revenue | 331.339 | 391.866 | 336.794 | 261.016 | 261.004 |
Total Operating Expense | -121.69 | 16.763 | 15.671 | 14.656 | 22.753 |
Selling/General/Admin. Expenses, Total | 63.538 | 16.187 | 13.883 | 14.656 | 22.753 |
Research & Development | 41.432 | 0.576 | 1.788 | 0 | 0 |
Operating Income | 453.029 | 375.103 | 321.123 | 246.36 | 238.251 |
Interest Income (Expense), Net Non-Operating | -162.707 | 73.799 | 33.47 | -13.12 | -22.294 |
Other, Net | -3.373 | -3.626 | -0.348 | -0.345 | -5.702 |
Net Income Before Taxes | 286.949 | 445.276 | 354.245 | 232.895 | 210.255 |
Net Income After Taxes | 220.262 | 368.837 | 293.814 | 190.993 | 406.328 |
Net Income Before Extra. Items | 213.921 | 265.854 | 224.402 | 157.288 | 395.056 |
Total Extraordinary Items | 0 | ||||
Net Income | 213.921 | 265.854 | 224.402 | 157.288 | 395.056 |
Income Available to Common Excl. Extra. Items | 213.921 | 265.854 | 224.402 | 157.288 | 395.056 |
Income Available to Common Incl. Extra. Items | 213.921 | 265.854 | 224.402 | 157.288 | 395.056 |
Diluted Net Income | 216.36 | 270.59 | 229.119 | 157.288 | 395.056 |
Diluted Weighted Average Shares | 95.248 | 94.31 | 113.554 | 113.409 | 113.408 |
Diluted EPS Excluding Extraordinary Items | 2.27154 | 2.86915 | 2.01771 | 1.38691 | 3.48349 |
Diluted Normalized EPS | 0.28877 | 2.86915 | 2.01771 | 1.38691 | 3.48349 |
Minority Interest | -6.341 | -102.983 | -69.412 | -33.705 | -11.272 |
Dilution Adjustment | 2.439 | 4.736 | 4.717 | ||
Cost of Revenue, Total | 13.793 | ||||
Gross Profit | 317.546 | ||||
Depreciation / Amortization | 5.581 | ||||
Unusual Expense (Income) | -246.034 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total revenue | 65.803 | 67.257 | 108.22 | 90.059 | 107.68 |
Revenue | 65.803 | 67.257 | 108.22 | 90.059 | 107.68 |
Total Operating Expense | 41.622 | -221.97 | 25.666 | 32.992 | 3.153 |
Selling/General/Admin. Expenses, Total | 17.454 | 27.81 | 11.782 | 6.492 | 3.113 |
Research & Development | 9.985 | 11.725 | 13.884 | 5.838 | 0.04 |
Operating Income | 24.181 | 289.227 | 82.554 | 57.067 | 104.527 |
Interest Income (Expense), Net Non-Operating | -86.246 | -2.831 | -61.531 | -12.099 | -46.448 |
Other, Net | -2.623 | 0.028 | -0.528 | -0.25 | -1.59 |
Net Income Before Taxes | -64.688 | 286.424 | 20.495 | 44.718 | 56.489 |
Net Income After Taxes | -68.314 | 229.347 | 21.371 | 37.858 | 45.65 |
Minority Interest | 0 | 36.176 | -20.432 | -22.085 | -35.305 |
Net Income Before Extra. Items | -68.314 | 265.523 | 0.939 | 15.773 | 10.345 |
Net Income | -68.314 | 265.523 | 0.939 | 15.773 | 10.345 |
Income Available to Common Excl. Extra. Items | -68.314 | 265.523 | 0.939 | 15.773 | 10.345 |
Income Available to Common Incl. Extra. Items | -68.314 | 265.523 | 0.939 | 15.773 | 10.345 |
Dilution Adjustment | 3.175 | 3.654 | 2.569 | 1.183 | |
Diluted Net Income | -68.314 | 268.698 | 4.593 | 18.342 | 11.528 |
Diluted Weighted Average Shares | 95.776 | 95.83 | 95.653 | 93.73 | 81.632 |
Diluted EPS Excluding Extraordinary Items | -0.71327 | 2.8039 | 0.04802 | 0.19569 | 0.14122 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Diluted Normalized EPS | -0.71327 | 0.57547 | 0.04802 | 0.38231 | 0.14122 |
Unusual Expense (Income) | 0 | -266.696 | 0 | 20.662 | |
Cost of Revenue, Total | 10.113 | 3.68 | |||
Gross Profit | 55.69 | 63.577 | |||
Depreciation / Amortization | 4.07 | 1.511 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 313.673 | 342.058 | 431.234 | 199.043 | 200.369 |
Cash and Short Term Investments | 201.525 | 246.487 | 350.845 | 114.908 | 129.075 |
Cash & Equivalents | 201.525 | 246.487 | 278.096 | 62.417 | 73.336 |
Short Term Investments | 0 | 72.749 | 52.491 | 55.739 | |
Total Receivables, Net | 110.711 | 93.931 | 79.427 | 83.286 | 70.54 |
Accounts Receivable - Trade, Net | 110.711 | 93.931 | 79.427 | 83.286 | 70.54 |
Prepaid Expenses | 1.437 | 1.64 | 0.962 | 0.849 | 0.754 |
Total Assets | 926.395 | 999.57 | 724.826 | 548.193 | 367.337 |
Property/Plant/Equipment, Total - Net | 0.012 | 0.028 | 0.033 | 0.16 | 0.209 |
Intangibles, Net | 111.43 | 125.253 | 139.076 | 152.899 | 166.722 |
Other Long Term Assets, Total | 17.435 | 93.973 | 154.483 | 196.091 | 0.037 |
Total Current Liabilities | 5.807 | 6.11 | 5.371 | 5.7 | 34.742 |
Accounts Payable | 0.027 | 0.066 | 0.01 | 0.011 | 0.601 |
Accrued Expenses | 5.78 | 6.044 | 5.361 | 5.689 | 9.141 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 25 | |||
Other Current Liabilities, Total | 0 | ||||
Total Liabilities | 511.652 | 459.658 | 411.331 | 394.61 | 610.196 |
Total Long Term Debt | 394.653 | 385.517 | 377.12 | 382.855 | 574.362 |
Long Term Debt | 394.653 | 385.517 | 377.12 | 382.855 | 574.362 |
Other Liabilities, Total | 0 | 0.106 | 0.219 | 0.586 | 0.94 |
Total Equity | 414.743 | 539.912 | 313.495 | 153.583 | -242.859 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.696 | 1.014 | 1.013 | 1.011 | 1.019 |
Additional Paid-In Capital | 1264.02 | 1260.9 | 1258.86 | 1256.27 | 1258.15 |
Retained Earnings (Accumulated Deficit) | -456.148 | -722.002 | -946.404 | -1103.69 | -1498.75 |
Treasury Stock - Common | -393.829 | 0 | -3.263 | ||
Other Equity, Total | 0 | 0.027 | -0.003 | -0.018 | |
Total Liabilities & Shareholders’ Equity | 926.395 | 999.57 | 724.826 | 548.193 | 367.337 |
Total Common Shares Outstanding | 69.5655 | 101.392 | 101.288 | 101.098 | 101.896 |
Minority Interest | 111.192 | 67.925 | 28.621 | 5.469 | 0.152 |
Long Term Investments | 483.845 | 438.258 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 317.823 | 313.673 | 236.928 | 148.261 | 372.933 |
Cash and Short Term Investments | 216.802 | 201.525 | 135.115 | 43.265 | 282.89 |
Cash & Equivalents | 216.802 | 201.525 | 135.115 | 43.265 | 282.89 |
Total Receivables, Net | 93.515 | 110.711 | 101.271 | 104.262 | 88.974 |
Accounts Receivable - Trade, Net | 93.515 | 110.711 | 101.271 | 104.262 | 88.974 |
Prepaid Expenses | 5.576 | 1.437 | 0.542 | 0.734 | 1.069 |
Total Assets | 1107.47 | 926.395 | 887.239 | 789.15 | 1088.29 |
Property/Plant/Equipment, Total - Net | 3.985 | 0.012 | 0.015 | 0.019 | 0.024 |
Intangibles, Net | 212.974 | 111.43 | 114.885 | 118.341 | 121.797 |
Long Term Investments | 544.437 | 483.845 | 507.116 | 473.677 | 519.325 |
Other Long Term Assets, Total | 22.711 | 17.435 | 28.295 | 48.852 | 74.211 |
Total Current Liabilities | 109.227 | 5.807 | 3.125 | 5.371 | 3.804 |
Accounts Payable | 1.808 | 0.027 | 0.089 | 0.03 | 0.014 |
Accrued Expenses | 11.403 | 5.78 | 3.036 | 5.341 | 3.79 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 720.832 | 511.652 | 484.428 | 459.37 | 453.829 |
Total Long Term Debt | 442.731 | 394.653 | 392.295 | 389.989 | 387.728 |
Long Term Debt | 442.731 | 394.653 | 392.295 | 389.989 | 387.728 |
Minority Interest | 165.575 | 111.192 | 88.994 | 63.965 | 62.22 |
Other Liabilities, Total | 3.299 | 0 | 0.014 | 0.045 | 0.077 |
Total Equity | 386.642 | 414.743 | 402.811 | 329.78 | 634.461 |
Common Stock | 0.696 | 0.696 | 0.695 | 0.695 | 1.014 |
Additional Paid-In Capital | 1182.91 | 1264.02 | 1262.44 | 1261.84 | 1261.33 |
Retained Earnings (Accumulated Deficit) | -403.137 | -456.148 | -466.493 | -538.931 | -627.879 |
Total Liabilities & Shareholders’ Equity | 1107.47 | 926.395 | 887.239 | 789.15 | 1088.29 |
Total Common Shares Outstanding | 69.594 | 69.5655 | 69.492 | 69.495 | 101.408 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Treasury Stock - Common | -393.829 | -393.829 | -393.829 | -393.829 | |
Other Current Assets, Total | 1.93 | ||||
Goodwill, Net | 5.544 | ||||
Current Port. of LT Debt/Capital Leases | 96.016 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | 368.837 | 293.814 | 190.993 | 406.328 | 134.272 |
Cash From Operating Activities | 363.813 | 313.113 | 257.458 | 223.531 | 141.749 |
Cash From Operating Activities | 13.832 | 13.84 | 13.874 | 13.872 | 13.982 |
Non-Cash Items | -78.415 | -40.639 | 7.621 | 16.145 | 21.775 |
Cash Interest Paid | 9.933 | 9.933 | 10.974 | 17.861 | 40.353 |
Changes in Working Capital | -16.873 | -14.322 | 3.095 | -16.76 | -28.28 |
Cash From Investing Activities | 43.722 | -314.937 | -18.003 | 3.519 | -23.236 |
Capital Expenditures | 0 | -0.013 | -0.012 | 0 | 0 |
Other Investing Cash Flow Items, Total | 43.722 | -314.924 | -17.991 | 3.519 | -23.236 |
Cash From Financing Activities | -452.497 | -29.785 | -23.776 | -237.969 | -163.193 |
Financing Cash Flow Items | -59.457 | -30.129 | -10.553 | -5.955 | 0.023 |
Total Cash Dividends Paid | 0 | 0 | -0.011 | -0.08 | -0.281 |
Issuance (Retirement) of Stock, Net | -393.04 | 0.344 | 0.538 | -1.934 | -99.193 |
Issuance (Retirement) of Debt, Net | 0 | 0 | -13.75 | -230 | -63.742 |
Net Change in Cash | -44.962 | -31.609 | 215.679 | -10.919 | -44.68 |
Deferred Taxes | 76.432 | 60.42 | 41.875 | -196.054 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 37.858 | 368.837 | 323.187 | 220.541 | 109.695 |
Cash From Operating Activities | 98.102 | 363.813 | 265.432 | 168.721 | 84.107 |
Cash From Operating Activities | 3.501 | 13.832 | 10.376 | 6.918 | 3.46 |
Deferred Taxes | 6.86 | 76.432 | 65.6 | 45.069 | 19.736 |
Non-Cash Items | 31.684 | -78.415 | -124.495 | -93.637 | -52.003 |
Cash Interest Paid | 5.411 | 9.933 | 9.933 | 4.967 | 4.967 |
Changes in Working Capital | 18.199 | -16.873 | -9.236 | -10.17 | 3.219 |
Cash From Investing Activities | -143.156 | 43.722 | 63.627 | 63.627 | -26.394 |
Capital Expenditures | -0.009 | 0 | 0 | 0 | 0 |
Other Investing Cash Flow Items, Total | -143.147 | 43.722 | 63.627 | 63.627 | -26.394 |
Cash From Financing Activities | 60.331 | -452.497 | -440.431 | -435.57 | -21.31 |
Financing Cash Flow Items | -6.507 | -59.457 | -46.358 | -41.446 | -21.285 |
Issuance (Retirement) of Stock, Net | 0.214 | -393.04 | -394.073 | -394.124 | -0.025 |
Net Change in Cash | 15.277 | -44.962 | -111.372 | -203.222 | 36.403 |
Total Cash Dividends Paid | 0 | ||||
Issuance (Retirement) of Debt, Net | 66.624 | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 14.3359 | 9766472 | 318524 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 10.3365 | 7041846 | 54802 | 2022-12-31 | LOW |
Sarissa Capital Management, L.P. | Hedge Fund | 9.7085 | 6614000 | 0 | 2022-12-31 | LOW |
Putnam Investment Management, L.L.C. | Investment Advisor/Hedge Fund | 7.3406 | 5000852 | 49183 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 6.2085 | 4229607 | -36066 | 2022-12-31 | HIGH |
Westfield Capital Management Company, L.P. | Investment Advisor/Hedge Fund | 6.0273 | 4106136 | 145968 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 4.7077 | 3207194 | 271075 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.3086 | 2253988 | -216906 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 3.1327 | 2134156 | -369816 | 2022-12-31 | HIGH |
Systematic Financial Management, L.P. | Investment Advisor | 2.8675 | 1953525 | 114784 | 2022-12-31 | LOW |
Assenagon Asset Management S.A. | Investment Advisor | 2.5143 | 1712874 | -190058 | 2022-12-31 | HIGH |
LSV Asset Management | Investment Advisor | 2.4093 | 1641361 | -1120342 | 2022-12-31 | LOW |
Pacer Advisors, Inc. | Investment Advisor | 2.2585 | 1538654 | 63256 | 2022-12-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7568 | 1196821 | 46886 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.4466 | 985539 | 147595 | 2022-12-31 | HIGH |
D. E. Shaw & Co., L.P. | Hedge Fund | 1.4372 | 979124 | 46803 | 2022-12-31 | MED |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.045 | 711936 | 164118 | 2022-12-31 | LOW |
BofA Global Research (US) | Research Firm | 0.9805 | 667991 | -8277 | 2022-12-31 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 0.9348 | 636816 | -350775 | 2022-12-31 | MED |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.9296 | 633331 | 25245 | 2022-12-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Innoviva Company profile
About Innoviva Inc
Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including, RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO and ELLIPTA. RELVAR/BREO is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS) and fluticasone furoate (FF). ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI. TRELEGY ELLIPTA a once-daily combination medicine consisting of an ICS, LAMA and LABA.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Innoviva Inc revenues increased 16% to $391.9M. Net income increased 18% to $265.9M. Revenues reflect Royalty revenue from a related party increase of 20% to $391.9M. Net income benefited from Changes in fair values of equity invest increase of 81% to $91M (income), Research and Development decrease of 68% to $576K (expense), Interest and dividend income increase of 21% to $1.8M (income).
Equity composition
Common Stock $.01 Par, 04/11, 200M auth., 74,693,843 issd. Insiders own 21.99%. IPO 10/04, 6.15M shares @ $16 per share by Merrill Lynch & Co. 07/10, Class A Common Stock $.01 Par, 30M auth., 9,401,499 issd. GlaxoSmithKline owns 100%.
Industry: | Pharmaceuticals (NEC) |
1350 Old Bayshore Highway
Suite 400
BURLINGAME
CALIFORNIA 94010
US
Income Statement
- Annual
- Quarterly
News

GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com